item management s discussion and analysis of financial condition and results of operations  our consolidated and combined financial statements  related notes and other financial information included herein 
historical results of operations and financial position are not necessarily indications of the results that may be expected in future periods 
year ended december  in thousands  except share and per share data consolidated and combined statement of operations data abraxane revenue other revenue net revenue cost of sales gross profit loss operating expenses research and development selling  general and administrative reacquisition costs amortization of intangible assets in process research and development merger related costs litigation costs impairment charge equity in net income of drug source company  llc total operating expense loss from operations interest income other expense interest expense loss before income taxes benefit provision for income taxes net loss basic and diluted loss per common share weighted average common shares outstanding basic diluted consolidated balance sheet data working capital deficit total assets total debt total stockholder s equity deficit other data cash flow used in provided by operating activities purchases of property plant and equipment cash flow provided by used in financing activities as of the completion of the separation on november   we had million common shares outstanding 
the same number of shares is being used for both diluted earnings per share and basic earnings per share for all periods prior to the separation date 
all potentially dilutive employee stock awards were excluded from the computation of diluted loss per common share for all periods as the effect on net loss per share was anti dilutive 

table of contents item management s discussion and analysis of financial condition and results of operations overview the following management s discussion and analysis of financial condition and results of operations  or md a is intended to assist the reader in understanding our company 
the md a is provided as a supplement to  and should be read in conjunction with the other sections of this annual report on form k  including item business  item a risk factors  item selected financial data  and 
